These nuances must be studied further if we ever hope to use CH in cancer therapy—both to develop novel strategies and optimize existing ones, whether that be targeting CH directly, incorporating CH as a prognostic and/or predictive biomarker, or leveraging CH in the TME to our benefit. The gene discussed is C4B; the disease is cancer.